Bright Minds Biosciences

Bright Minds Biosciences, Inc. is a biotechnology company, which engages in the development of therapeutics. The company was founded by Ian B. McDonald and Alan P. Kozikowski on May 31, 2019 and is headquartered in New York, NY.

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

-- Herbert Y. Meltzer, MD; Karl Deisseroth, MD, PhD; Robert C. Malenka, MD, PhD; Michael P. Bogenschutz, MD; and Peter Hendricks, PhD, bring decades of clinical and research expertise in psychiatry, addiction, behavioral health, and pharmacology to guide Company's development programs -- --Scientific Advisory Board members are affiliated with cutting-edge programs at elite academic and medical institutions --

Bright Minds Biosciences Establishes Scientific Advisory Board, Comprising Five Preeminent Physicians and Scientists Across Mental Health Specialties

With the COVID-19 pandemic upending life in every corner of the world and putting unwelcome pressure on people vulnerable to depression, suicide and addiction, there has never been a better time to consider new treatments for mental health challenges. One field gaining particularly rapid traction is psychedelics.

Bright Minds Biosciences: A vision for “next generation” psychedelic medicines to treat neurological conditions

— Hundreds of de novo patentable psychedelic-based compounds created through discovery program —

Bright Minds Biosciences Provides Scientific Update on its Novel 5-HT2A Psychedelic Program for the Treatment of Mental Diseases

Wall Street is welcoming yet another company working with psychedelic molecules for mental health and neurological treatments. Bright Minds Biosciences (CSE:DRUG) received approval on Wednesday to effectively list its stock on the Nasdaq starting next Monday, November 8 under the symbol “DRUG.

Bright Minds Biosciences: Newest Psychedelics Company To Join The Nasdaq

VANCOUVER, British Columbia, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for targeted treatment of neuropsychiatric disorders, epilepsy and pain, today announced that The Nasdaq Stock Market LLC has approved the listing of the Company's common stock on The Nasdaq Capital Market (“Nasdaq”). Effective November 8, the shares will commence trading under the ticker symbol “DRUG.” Bright Minds will continue to maintain the listing of its Shares on the Canadian Stock Exchange (“CSE”) under the symbol “DRUG.”

Bright Minds Biosciences Commences Trading on the Nasdaq Under the Ticker Symbol “DRUG”

News for Bright Minds Biosciences Stock (DRUG)